Cargando…

Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China

BACKGROUND: Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. METHODS: This study retrospectively included 59 patients with ASCC a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yan, Xie, Wei‐Hao, Li, Rong‐Zhen, Chang, Hui, Zeng, Zhi‐Fan, Gao, Yuan‐Hong, Wang, Qiao‐Xuan, Xiao, Wei‐Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704146/
https://www.ncbi.nlm.nih.gov/pubmed/34816622
http://dx.doi.org/10.1002/cam4.4433
_version_ 1784621637136547840
author Yuan, Yan
Xie, Wei‐Hao
Li, Rong‐Zhen
Chang, Hui
Zeng, Zhi‐Fan
Gao, Yuan‐Hong
Wang, Qiao‐Xuan
Xiao, Wei‐Wei
author_facet Yuan, Yan
Xie, Wei‐Hao
Li, Rong‐Zhen
Chang, Hui
Zeng, Zhi‐Fan
Gao, Yuan‐Hong
Wang, Qiao‐Xuan
Xiao, Wei‐Wei
author_sort Yuan, Yan
collection PubMed
description BACKGROUND: Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. METHODS: This study retrospectively included 59 patients with ASCC admitted from 1975 to 2018 in Sun Yat‐sen University cancer center. The clinical records and follow‐up information of all patients were collected. Survival analysis and univariate and multivariate regression analyses were performed using the “survival” and “survminer” packages of R software. RESULTS: In 59 patients, 5 patients had distant metastasis at diagnosis. Among 54 M0 stage patients, 33 patients received chemoradiotherapy (CRT), 19 patients received local surgery, and 2 patients refused curative treatment and received the best supportive treatment (BST). The most common grade 3–4 acute toxicities during treatment were myelosuppression and radiation dermatitis. The median follow‐up time was 32 months. For the whole group, the 3‐year and 5‐year overall survival (OS) rates and disease‐free survival (DFS) were 71.1% and 63.6%, and 73.4% and 69.0%, respectively. Multivariate regression analysis showed that the T3–4 stage was an independent prognostic risk factor for OS, progression‐free survival (PFS), and DFS. And M1 was an independent prognostic risk factor for PFS and DFS. Patients in stage M0 mainly treated with CRT had better local control than those mainly treated with surgery (p = 0.027). For M0 patients, induction chemotherapy combined with CRT tends to prolong OS compared with CRT alone (p = 0.26). The 3‐year colostomy‐free survival for the whole group was 81.1%. CONCLUSIONS: CRT is recommended as the first choice for the treatment of M0 stage ASCC. Induction chemotherapy may bring better survival benefits for some patients. Patients with ASCC in China seem to have a better local control rate, which suggested different treatment strategies may be needed in China.
format Online
Article
Text
id pubmed-8704146
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87041462022-01-04 Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China Yuan, Yan Xie, Wei‐Hao Li, Rong‐Zhen Chang, Hui Zeng, Zhi‐Fan Gao, Yuan‐Hong Wang, Qiao‐Xuan Xiao, Wei‐Wei Cancer Med Clinical Cancer Research BACKGROUND: Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. METHODS: This study retrospectively included 59 patients with ASCC admitted from 1975 to 2018 in Sun Yat‐sen University cancer center. The clinical records and follow‐up information of all patients were collected. Survival analysis and univariate and multivariate regression analyses were performed using the “survival” and “survminer” packages of R software. RESULTS: In 59 patients, 5 patients had distant metastasis at diagnosis. Among 54 M0 stage patients, 33 patients received chemoradiotherapy (CRT), 19 patients received local surgery, and 2 patients refused curative treatment and received the best supportive treatment (BST). The most common grade 3–4 acute toxicities during treatment were myelosuppression and radiation dermatitis. The median follow‐up time was 32 months. For the whole group, the 3‐year and 5‐year overall survival (OS) rates and disease‐free survival (DFS) were 71.1% and 63.6%, and 73.4% and 69.0%, respectively. Multivariate regression analysis showed that the T3–4 stage was an independent prognostic risk factor for OS, progression‐free survival (PFS), and DFS. And M1 was an independent prognostic risk factor for PFS and DFS. Patients in stage M0 mainly treated with CRT had better local control than those mainly treated with surgery (p = 0.027). For M0 patients, induction chemotherapy combined with CRT tends to prolong OS compared with CRT alone (p = 0.26). The 3‐year colostomy‐free survival for the whole group was 81.1%. CONCLUSIONS: CRT is recommended as the first choice for the treatment of M0 stage ASCC. Induction chemotherapy may bring better survival benefits for some patients. Patients with ASCC in China seem to have a better local control rate, which suggested different treatment strategies may be needed in China. John Wiley and Sons Inc. 2021-11-24 /pmc/articles/PMC8704146/ /pubmed/34816622 http://dx.doi.org/10.1002/cam4.4433 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Yuan, Yan
Xie, Wei‐Hao
Li, Rong‐Zhen
Chang, Hui
Zeng, Zhi‐Fan
Gao, Yuan‐Hong
Wang, Qiao‐Xuan
Xiao, Wei‐Wei
Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China
title Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China
title_full Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China
title_fullStr Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China
title_full_unstemmed Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China
title_short Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China
title_sort comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in south china
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704146/
https://www.ncbi.nlm.nih.gov/pubmed/34816622
http://dx.doi.org/10.1002/cam4.4433
work_keys_str_mv AT yuanyan comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT xieweihao comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT lirongzhen comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT changhui comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT zengzhifan comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT gaoyuanhong comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT wangqiaoxuan comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina
AT xiaoweiwei comprehensivetreatmentexperienceofanalsquamouscellcarcinomafromatertiarycancercenterinsouthchina